Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Status:
Terminated
Trial end date:
2020-11-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the anti-tumor activity, as measured by
overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with
chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an
international, open-label single arm (non-randomized), one-stage phase II trial.
Phase:
Phase 2
Details
Lead Sponsor:
Vall d'Hebron Institute of Oncology
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC